Secondary progressive multiple sclerosis (SPMS) is a later stage of the chronic disease multiple sclerosis MS.
Most people with MS start out with a clinical course characterized by episodes or attacks (relapses) of neurologic dysfunction, which occur over many years. This is called the relapsing-remitting phase. Symptoms of such relapses include vision loss or double vision, numbness/tingling in the extremities, muscle weakness, slurred speech, difficulty with coordination, and bladder dysfunction. Unlike the first phases of MS, SPMS gets steadily worse and relapses are no longer likely. SPMS can be difficult to diagnose.
Limited approved MS and SPMS therapies are currently available. Meridian is conducting a Phase III clinical trial for an investigational medication for people with SPMS.
- Must be age 18 to 60
- Must be diagnosed with SPMS
- Must have an absence of clinical relapses for 24 months
- Must have documented evidence of 12 months of disability progression
- May receive compensation for time and travel
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.
You can also talk to a Meridian enrollment specialist about this study by calling (912) 354-7676.
Submit your information
Meridian Clinical Research
6602 Waters Avenue, Building C
Savannah, GA 31406
Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services. Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.